Fewer than 200 of an estimated 600–800 GCC Dravet syndrome patients are molecularly SCN1A-confirmed — and cannabidiol, the most effective agent in pivotal trials, remains unregistered in the region.
Dravet syndrome is a severe SCN1A-related developmental and epileptic encephalopathy, with an estimated GCC prevalence-derived burden of 600–800 patients (based on a 1:15,700 global prevalence rate applied to a roughly 12 million paediatric population). Molecular confirmation via SCN1A genetic testing is available at only 5–6 centres across the GCC — KFSH&RC, AUH, and Sidra Medicine combined account for fewer than 200 molecularly confirmed cases, meaning roughly 70% of the estimated population lacks the genetic documentation required for specialist Dravet-specific therapy. Testing turnaround runs 4–8 weeks, and some centres require pre-test genetic counselling; many physicians instead treat clinically probable Dravet without molecular confirmation, missing the documentation novel therapies typically require.
Dravet syndrome carries a lifetime SUDEP risk of 2–18% and an early-mortality rate of 15–20%, driven by infections and status epilepticus; GCC-specific SUDEP data remain limited, but regional mortality is estimated to run higher than the global average because of delayed SCN1A diagnosis, the absence of cannabidiol (the most effective agent in pivotal trials), and limited ketogenic diet infrastructure (only 8–10 GCC hospitals run a structured programme). Sodium channel blockers (carbamazepine, phenytoin) are contraindicated in SCN1A-related Dravet and worsen seizures; awareness of this contraindication is increasingly established across GCC specialist paediatric neurology centres, even where the SCN1A test itself remains hard to access.
GCC Dravet syndrome disease burden — three defining dimensions
| Dimension | GCC Finding | Comparator | Implication |
|---|---|---|---|
| Diagnosis rate | 600–800 estimated patients; fewer than 200 molecularly confirmed | SCN1A testing at only 5–6 GCC centres; 4–8 week turnaround | Molecular confirmation gap directly limits the specialist-therapy-eligible population |
| Therapeutic access | Stiripentol accessible via specialist prescription; cannabidiol not GCC-registered | Cannabidiol shows 38.9% seizure reduction in GWPCARE1-4 | Regulatory restriction on cannabidiol is the dominant commercial barrier in the GCC |
| Mortality burden | 15–20% early mortality; 2–18% lifetime SUDEP risk | 8–10 GCC hospitals run structured ketogenic diet programmes | Seizure freedom and SUDEP risk, not convenience, drive caregiver treatment priorities |
Sources: KFSH&RC, AUH, and Sidra Medicine paediatric epilepsy genetics programmes (2022); Dravet Syndrome Foundation SUDEP statistics; GCC paediatric epilepsy genetics consensus 2022; Dravet Syndrome International Working Group; SFDA registration records.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- SCN1A testing capacity and turnaround mapping
- clinical-vs-molecular diagnosis gap sizing
- addressable population modelling
Delivers
- GCC cannabidiol regulatory restriction analysis
- exceptional-import approval-rate benchmarking
- comparative regulatory-pathway assessment for pipeline agents
Delivers
- GCC standard-of-care sequencing
- ketogenic diet centre network (8–10 hospitals)
- SUDEP risk communication and caregiver priorities
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why Dravet syndrome is a severe SCN1A-related developmental and epileptic encephalopathy with an estimated GCC burden of 600 to 800 patients.
- How sodium channel blockers like carbamazepine and phenytoin are contraindicated in SCN1A-related Dravet and can worsen seizures.
- How the 600 to 800 estimated GCC Dravet patients, derived from a 1:15,700 global prevalence rate applied to a 12 million paediatric population, compare against fewer than 200 molecularly confirmed cases.
- Why roughly 70% of the estimated population lacks the SCN1A genetic documentation required for specialist Dravet-specific therapy.
- Why SCN1A testing exists at only 5 to 6 GCC centres, KFSH&RC, AUH, and Sidra Medicine among them, with a 4 to 8 week turnaround.
- How pre-test genetic counselling requirements at some centres push physicians to treat clinically probable Dravet without the molecular confirmation novel therapies typically require.
- Why Dravet syndrome carries a lifetime SUDEP risk of 2 to 18% and an early-mortality rate of 15 to 20%, driven by infections and status epilepticus.
- How regional mortality is estimated to run higher than the global average given delayed SCN1A diagnosis and limited ketogenic diet infrastructure across only 8 to 10 GCC hospitals.
- How stiripentol remains accessible via specialist prescription while cannabidiol, showing a 38.9% seizure reduction in GWPCARE1-4, is not GCC-registered.
- Why regulatory restriction on cannabidiol, limited to exceptional or named-patient import, is the dominant commercial barrier in the GCC.
- How SFDA registration records and GCC import and distribution channels, not US or EU payer language, define the regulatory pathway for stiripentol and cannabidiol.
- Why the specialist centre network anchored at KFSH&RC, AUH, and Sidra Medicine determines both molecular diagnosis and treatment access across the GCC.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment is built from the KFSH&RC, AUH, and Sidra Medicine paediatric epilepsy genetics programmes and Dravet Syndrome International Working Group consensus documents, triangulated to separate estimated Dravet prevalence from molecularly confirmed diagnoses.
Regulatory status for cannabidiol and stiripentol is confirmed against SFDA registration records and current GCC import/distribution channels rather than US/EU payer language, reflecting the region's exceptional-import pathway for restricted controlled substances.
- SCN1A testing centre count and confirmation rate verified against KFSH&RC, AUH, and Sidra Medicine paediatric epilepsy genetics programme data (2022).
- Mortality and SUDEP risk figures verified against Dravet Syndrome Foundation SUDEP statistics and Dravet Syndrome International Working Group consensus guidance; GCC-specific SUDEP incidence data remain limited relative to global Dravet registries.
- SCN1A/GEFS+ spectrum distinction verified against GCC paediatric epilepsy genetics consensus 2022 and Dravet Syndrome International Working Group guidance
- Cannabidiol and stiripentol regulatory/import status confirmed against current SFDA registration and GCC distributor records
Frequently asked questions
Commission this assessment
AXLRx Dravet Syndrome Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the GCC Dravet patient population. Custom assessment in 72 hours.
Specify indication, GCC country focus, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.